BOLT

Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BOLT

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/21	02 : 22	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/05/16	06 : 43	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/05/15	05 : 14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/05/15	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/05/15	05 : 05	GlobeNewswire Inc.	Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/03/22	05 : 05	GlobeNewswire Inc.	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/03/07	03 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/03/07	03 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/02/27	21 : 00	GlobeNewswire Inc.	Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/02/13	11 : 41	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2024/02/07	03 : 09	Edgar (US Regulatory)	Form 5 - Annual statement of changes in beneficial ownership of securities	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/12/21	21 : 30	GlobeNewswire Inc.	Pacira Appoints Frank D. Lee as Chief Executive Officer	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/12/14	03 : 40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/12/05	21 : 00	GlobeNewswire Inc.	Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/11/10	06 : 10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/11/10	06 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/11/10	06 : 05	GlobeNewswire Inc.	Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/11/07	21 : 00	GlobeNewswire Inc.	Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/10/23	23 : 30	GlobeNewswire Inc.	Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/10/18	20 : 00	GlobeNewswire Inc.	Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/10/17	20 : 00	GlobeNewswire Inc.	Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/10/16	20 : 00	GlobeNewswire Inc.	Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/09/28	20 : 00	GlobeNewswire Inc.	Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/09/12	21 : 05	GlobeNewswire Inc.	Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/09/06	05 : 15	GlobeNewswire Inc.	Bolt Biotherapeutics to Participate in September Investor Conferences	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/08/08	05 : 10	GlobeNewswire Inc.	Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/08/08	05 : 08	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/08/08	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/08/03	20 : 30	GlobeNewswire Inc.	Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer	NASDAQ:BOLT	Bolt Biotherapeutics Inc
2023/08/01	06 : 27	GlobeNewswire Inc.	Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023	NASDAQ:BOLT	Bolt Biotherapeutics Inc